Unique Convert Offering From Dendreon via JPMorgan
After the bell yesterday Dendreon announced a $500 million convertible debt offering run by JPMorgan. Those who read past the headline might notice the deal is a bit unusual.
After the bell yesterday Dendreon (DNDN) announced a $500 million (+$75 million greenshoe) convertible debt offering run by JPMorgan (JPM). Those who read past the headline might have noticed the deal is a bit unusual. Before I describe it, a quick primer:
When a company issues convertible debt, the convertible arbitrage funds who buy it will short the stock in the open market. This pressures the stock price. The convert arb funds who buy the deal overnight want to hedge right away, so the pressure on the stock could be quite bad the trading day after the announcement. JPM structured this deal to try to eliminate that problem.
Any convert arb fund who wants in the deal and who wants to hedge agrees to do their hedge with JPM at a pre-negotiated price. JPM turns around and sells those shares to other buyers at a negotiated price. This keeps all the "normal" hedging/shorting off the regular market. The deal bidding and pricing -- which includes the convert terms, the hedge share price, and price funds will buy stock from JPM at -- all occurs while the deal was being marketed.
If everything works, the deal should prevent 6 million to 7 million short shares from hitting the bid/ask on Friday morning. Those shares still end up on the Nasdaq reported short interest, but the common shares (and existing DNDN shareholders) could escape the selling pressure normally accompanying a convertible debt offering.
If this works as expected, investors should see more of this structure.
I'll note that fast money traders often reflexively short convert deals because of how they normally work. In my opinion, we'll see some of that this morning. If I was in that business, I'd be cautious about shorting this one. Normally, you'd have the convert buyers as company. In this structure, you'll only have other opportunistic traders. That could result in a small short squeeze as these reflexive traders figure out too late this is a unique deal structure.
The deal, which sources tell me matures in 2016, also provides the right for DNDN to repay the debt in cash. If they do that, and they should have more than enough cash flow to do so by 2016 if Provenge sells as projected, there won't be any shareholder dilution from this deal.
See also Debate Over Dendreon's Provenge Coverage Is Settled for why investors no longer have to wait until March to feel confident buying Dendreon.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.